{"denoms":[{"counts":[{"groupId":"BG000","value":"138"}],"units":"Participants"}],"groups":[{"description":"Participants received alectinib at a dose of 600 mg via capsule, orally, twice daily, continuously starting on Day 1 Cycle 1 (in 28-day cycles) until PD, death, or withdrawal for any other reasons, whichever occurred first. After PD, participants were allowed to continue treatment with alectinib as per the discretion of the treating physician.","id":"BG000","title":"Alectinib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.1","value":"51.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"77"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"61"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Analysis was performed on safety population, which included all participants who received at least one dose of alectinib."}